DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Olprinone
Olprinone
Phosphodiesterase (PDE)
Xagrid, INN-Anagrelide
(12) Patent Application Publication (10) Pub. No.: US 2009/0246185 A1 Kishida Et Al
Customs Tariff - Schedule
Nivedita Singh
Phosphodiesterases As Therapeutic Targets for Respiratory Diseases
Stembook 2018.Pdf
Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
Olprinone, a Phosphodiesterase III Inhibitor, Reduces Gut Mucosal
(12) Patent Application Publication (10) Pub. No.: US 2008/0200484 A1 Liu Et Al
Pharmaabkommen A1 E
Customs Tariff - Schedule Xxi - 1
Wo 2007/044693 A2
Human Neurogenesis Assay: Ramelteon
(51) International Patent Classification: (74) Agent: HARRIS, Bob Et Al.; Viksnins Flarris Padys Malen A61K 31/4725 (2006.01) A6
A Pathophysiological Role of PDE3 in Allergic Airway Inflammation
Top View
Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
AGRYLIN (Anagrelide Hydrochloride)
Harmonized Tariff Schedule of the United States (2006) (Rev
Neurogenesis Via Modulation of the Muscarinic Receptors
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Drug Repurposing Compound Library Plus (96-Well)
Download Leaflet View the Patient Leaflet in PDF Format
Xagrid, INN-Anagrelide Hydrochloride
Pharmaceuticals and Medical Devices Safety Information No
Special Article
1111111111111111111Imnumu
(12) United States Patent (10) Patent No.: US 7,985,756 B2 Barlow Et Al
Short-Term Cardiovascular Effects of Selective
Agrylin® Capsules
(12) United States Patent (10) Patent No.: US 9,000,147 B2 Sauve Et Al
Package Leaflet: Information for the Patient Anagrelide AOP 0.5 Mg
Schedule Clxxiii - European Union